AlphAIAlphAI — Financial news for AI agents
investing.comOCT 81 min read$NRXS

Neuraxis CRO Carrico buys $1,587 in common stock

Neuraxis CRO Thomas Carrico bought 328 shares at $4.84 each, totaling $1,587. He now holds 199,673 shares. NRXS shares are up 40% since his purchase and 116% over the past year. Neuraxis reported Q2 2026 revenue growth of 116% to $1.928 million but a wider loss of $0.19 per share. The company's gross margins improved.

Original reporting
investing.com
Published Oct 8, 2026, 10:16 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 9, 2026, 5:01 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefFinancial news
Primary signal
$NRXS
Bullish
medium confidence
Mentioned
$NRXS
Relevance
4/10
AlphAI data visualization · based on investing.com
Decision brief

The 30-second read

$NRXSBullishLow
01

Why it matters

The insider purchase adds a modest bullish signal amid mixed earnings.

02

Market read

Small insider buy in a microcap with recent earnings beat may provide slight upside bias.

03

What to watch

Potential upcoming earnings or product news could dominate price movement.

Relevance 4/10Novelty 4/10Timing: today

Background

Neuraxis (NRXS) reported Q2 2026 revenue growth but a wider-than-expected loss.

Company-level read

Ticker impact

$NRXSBullishMedium confidence
Context

Form 4 filing shows CRO Thomas Carrico bought 328 shares at $4.84, a $1,587 insider purchase.

Expected impact

likely upward pressure as the market prices in insider confidence

Evidence & confidence

The purchase is small but represents a 40% gain from the purchase price, indicating confidence from a senior executive.

Market effects

Sector

Minimal impact on the broader AI/tech sector.

Regional

Limited to US small-cap investors.

Global

None

Counterpoint

What could challenge this read

The purchase size is too small to affect price; market may ignore it.

Key entities

  • Executive
    Thomas Joeseph Carrico

    Chief Revenue Officer, Chief Compliance Officer, and Chief Privacy Officer at Neuraxis.

Read at source← All news

Related articles

SEP 16
$NRXSHighAI 8/10

NeurAxis Expands PENFS Coverage By 18 Million Lives As IB-Stim Adoption Grows; Stock Up

NeurAxis (NRXS) announced that a major national insurer expanded coverage for its PENFS therapy, adding 18 million members, bringing total coverage to 120 million. The company's IB-Stim device is FDA-cleared for pediatric abdominal pain. CEO Brian Carrico highlighted growth acceleration and plans to pursue additional insurers. NRXS stock is up 21.77% to $6.94.

rttnews.com2 min
SEP 16
$NRXSHigh

NeurAxis secures major insurer coverage for IB-Stim device

NeurAxis (NRXS) announced a major national health insurer will cover its IB-Stim device for treating abdominal pain in patients aged 8+. The coverage applies to 18M members across multiple states. The FDA-cleared device is a non-invasive neuromodulation technology. NeurAxis aims to secure coverage from more insurers and is conducting additional clinical trials. The company did not disclose the insurer's name or provide financial projections.

investing.com2 min
SEP 16
$NRXSMed

NeurAxis Announces Medical Coverage Policy Milestone, Expanding Access to Over 18 million additional Covered Lives

NeurAxis (NRXS) announced a new medical policy coverage from a major national health insurer for its Percutaneous Electrical Nerve Field Stimulation (PENFS) technology, IB-Stim, expanding access to 18 million members. IB-Stim is FDA-cleared for treating functional abdominal pain in children and adults. The company aims to broaden payer coverage and increase commercialization, citing a strong foundation and potential for revenue growth.

globenewswire.com2 min